A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics JA, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, Swanton C. 2016. Challenges in molecular testing in non-smallcell lung cancer patients with advanced disease. Lancet. 388:1002–1011. doi:10.1016/S0140-6736(16)31340-X.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Socinski MA. 2009. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc. 6:233–241. doi:10.1513/pats.200809-110LC.
   PubMedGoogle Scholar
• Acquaviva J, Wong R, Charest A. 2009. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 1795:37–52. doi:10.1016/j.bbcan.2008.07.006.
   PubMed Web of Science ®Google Scholar
• Davies KD, Le AT, Theodoro MF, Skokan M C, Aisner D L, Berge E M, Terracciano L M, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge D R, Varella-Garcia M, Doebele R C. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18:4570–4579. doi:10.1158/1078-0432.CCR-12-0550.
   PubMed Web of Science ®Google Scholar
• Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K. 2015. Beyond ALK, RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 4:156–164. doi:10.3978/j.issn.2218-6751.2014.11.11.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular profiling of lung adenocarcinoma. Nature. Cancer Genome Atlas Research Network. 2014. 511(7511):543–550. doi:10.1038/nature13385.
   Google Scholar
• Zhu VW, Upadhyay D, Schrock AB, Gowen K, Ali SM, Ou S-HI. 2016. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. Lung Cancer. 97:48–50. doi:10.1016/j.lungcan.2016.04.013.
   PubMed Web of Science ®Google Scholar
• Gounder M M, Hakimi A A, Harding J J, Zehir A, Benayed R, Shah R H, Syed A, Middha S, Kim H R, Srinivasan P, Gao J, Chakravarty D, Devlin S M, Hellmann M D, Barron D A, Schram A M, Hameed M, Dogan S, Ross D S, Hechtman J F, DeLair D F, Yao J, Mandelker D L, Cheng D T, Chandramohan R, Mohanty A S, Ptashkin R N, Jayakumaran G, Prasad M, Syed M H, Rema A B, Liu Z Y, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka I J, Razumova A, Son J B, Stewart L, Baldi T, Mullaney K A, Al-Ahmadie H, Vakiani E, Abeshouse A A, Penson A V, Jonsson P, Camacho N, Chang M T, Won H H, Gross B E, Kundra R, Heins Z J, Chen H W, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas S B, Gardos S M, Reales D N, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman D R, Gounder M M, Hakimi A A, Harding J J, Iyer G, Janjigian Y Y, Jordan E J, Kelly C M, Lowery M A, Morris LGT, Omuro A M, Raj N, Razavi P, Shoushtari A N, Shukla N, Soumerai T E, Varghese A M, Yaeger R, Coleman J, Bochner B, Riely G J, Saltz L B, Scher H I, Sabbatini P J, Robson M E, Klimstra D S, Taylor B S, Baselga J, Schultz N, Hyman D M, Arcila M E, Solit D B, Ladanyi M, Berger M F. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–713. doi:10.1038/nm.4333.
   PubMed Web of Science ®Google Scholar
• Zhu YC, Zhou YF, Wang WX, Xu C-W, Zhuang W, Du K-Q, Chen G. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing. Thorac Cancer. 2018 Mar 8; Epub ahead of print. doi:10.1111/1759-7714.12617.
   Web of Science ®Google Scholar
• Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, Sekine I, Tamura T, Asamura H, Furuta K, Tsuda H. 2012. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol. 7:331–339. doi:10.1097/JTO.0b013e318241655f.
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. 2007. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6:3314–3322. doi:10.1158/1535-7163.MCT-07-0365.
   PubMed Web of Science ®Google Scholar
• Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. 2012. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 7:1086–1090. doi:10.1097/JTO.0b013e3182570919.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, et al. 2014. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 371:1963–1971. doi:10.1056/NEJMoa1406766.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–2772. doi:10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Varghese AM, Ou S-HI, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, et al. 2013. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 19:4273–4281. doi:10.1158/1078-0432.CCR-13-0318.
   PubMed Web of Science ®Google Scholar
• Ju L, Han M, Zhao C, Li X. 2016. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient. Lung Cancer. 95:94–97. doi:10.1016/j.lungcan.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Xu C-W, Zhu Y-C, Ye X-Q, Yin M-X, Zhang J-X, Du K-Q, Zhang Z-H, Hu J. 2016. Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. OncoTargets and Therapy. 9:4301–4305. doi:10.2147/OTT.
   PubMed Web of Science ®Google Scholar
• Tang Z, Zhang J, Lu X, Wang W, Chen H, Robinson MK, Cheng J, Tang G, Medeiros LJ. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Mod Pathol. 2018;31(2):307–312. doi:10.1038/modpathol.2017.109.
   PubMed Web of Science ®Google Scholar
• Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel PA, Schirmacher P, Penzel R, Weichert W. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology. 2014;65(2):187–194. doi:10.1111/his.12379.
   PubMed Web of Science ®Google Scholar
• Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, et al. High prevalence of concomitant oncogene mutations in prospectively identified patients with ros1-positive metastatic lung cancer. J Thorac Oncol. 2017;12(1):54–64. doi:10.1016/j.jtho.2016.08.137.
   PubMed Web of Science ®Google Scholar
• Song ZB, Zheng YH, Zhang YP. ALK and ROS1 rearrangements, coexistence and treatment in EGFR-wild type lung adenocarcinoma - A multicenter study of 732 cases. J Thorac Oncol. 2017;12(1):s1160–s1161. doi:10.1016/j.jtho.2016.11.1633. http://www.jto.org/article/S1556-0864(16)32874-X/fulltext.
   Web of Science ®Google Scholar
• Wang P, Xiao P, Ye Y, Liu P, Han L, Dong L, She C, Yu J. Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report. Cancer Biol Med. 2017;14(2):183–186. doi:10.20892/j.issn.2095-3941.2017.0017.
   PubMed Web of Science ®Google Scholar
• Coccé MC, Mardin BR, Bens S, Stütz AM, Lubieniecki F, Vater I, Korbel JO, Siebert R, Alonso CN, Gallego MS. Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3). Genes Chromosomes Cancer. 2016;55(9):677–687. doi:10.1002/gcc.22369.
   PubMed Web of Science ®Google Scholar
• Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K. Phase II study of crizotinib in East Asian Patients With ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;29:JCO2017755587. Epub ahead of print. doi:10.1200/JCO.2017.75.5587.
   Google Scholar
• Ou S-HI, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang Y-J, et al. 2011. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 6:942–946. doi:10.1097/JTO.0b013e31821528d3.
   PubMed Web of Science ®Google Scholar
• Caparica R, Yen CT, Coudry R, Ou S-HI, Varella-Garcia M, Camidge DR, De Castro G. Responses to crizotinib can occur in high-level MET-amplified non-small cell lung cancer independent of MET Exon 14 alterations. J Thorac Oncol. 2017;12(1):141–144. doi:10.1016/j.jtho.2016.09.116.
   PubMed Web of Science ®Google Scholar